T3D Therapeutics Signs Exclusive License Agreement for T3D-959 (DB959) and Related Compounds
DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology supportive care products, announced today that it has granted T3D Therapeutics, Inc. the exclusive worldwide rights to develop and commercialize DB959. DB959 is an oral,...
T3D Therapeutics adds Dr. Bruce Burnett to its Advisory Board
Bruce K. Burnett, PhD, RAC (US, EU) is Director of Regulatory Affairs at Duke Translational Medicine Institute. Dr. Burnett received his undergraduate degree in organic chemistry from the University of California, San Diego and his PhD in organic...
T3D Therapeutics, an Alzheimer’s Disease-Focused Company, Selected to Present at the SEBIO Investor and Partnering Forum
T3D Therapeutics will introduce T3D-959, a transformational new drug therapy in development for the treatment of Alzheimer's disease. Read More
T3D Therapeutics adds Dr. Lawrence Friedhoff, Dr. Warren Strittmatter and Dr. Joseph DeVeaugh-Geiss to its Advisory Board
T3D Therapeutics announced the creation of its Advisory Board with the addition of three members who are experts in the field of Alzheimer’s disease and other central nervous system disorders; Lawrence Friedhoff, M.D., Ph.D., FACP, Warren Strittmatter, M.D. and Joseph...
T3D Therapeutics Appoints Dr. Charles Lineberry and Barry Buzogany to its Board of Directors
T3D Therapeutics announced the appointment of Charles Lineberry, Ph.D. and Barry Buzogany, Esq. to its Board of Directors. Dr. Lineberry, founder and president of Lineberry Research Associates, has a Ph.D. in physiological psychology, NIH post-doctoral training in...